Skip to main content
OpenTrials
Completed

NCT Number: NCT01965522

Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer

Investigators plan to carry out a study to investigate two different pills, Vitamin D and melatonin, and whether they can reduce the spread of cancer cells in the tumors of women with breast cancer. These pills are inexpensive and have very few side effects. A large number of studies using cell cultures and animals have shown that both vitamin D and melatonin can help destroy breast cancer cells. However thoughtful and well-designed studies are necessary on humans to see if they can decrease the spread of breast cancer, and possibly even prevent breast cancer. The proposed study aims to understand the anti-cancer activity of vitamin D and melatonin. This knowledge will assist in creating efficient cancer prevention strategies for Canadians. This study will include women with breast cancer who are being planned for surgery, and will assess whether treatment with vitamin D (dose of 2000 IU per day) in a group of 36 women, or melatonin (dose of 20mg per day) in another group of 36 women, or both pills together in yet another group of 36 women, reduces the spread of cancer cells when compared to a fourth group of 36 women who are treated with sugar pills. To do this we will measure a substance in the blood called Ki67, which provides information about the spread of cancer. Investigators will compare the Ki67 levels in the 4 groups, and all women will receive identical appearing pills so they will not know which treatment they received.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Early Stage Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Juravinski Cancer Center, Hamilton, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Woman with histologically confirmed invasive breast cancer (ductal, lobular, or mixed)
  • Planned to undergo definitive surgery, either lumpectomy or mastectomy in 3 or more weeks

Exclusion criteria

  • Less than 18 years of age
  • Stage IIIB or IV disease
  • Inoperable locally advanced or metastatic breast cancer
  • Neoadjuvant chemotherapy is intended
  • Currently taking vitamin D supplements
  • Currently taking melatonin supplements
  • Previously taking vitamin D or melatonin supplements within the last 3 months
  • Currently taking a multivitamin and not willing to discontinue for the duration of the study
  • Hyperparathyroid disease or other calcium disturbance in the past five years
  • Active renal stones in the last six months
  • Renal failure (creatinine > 190 mmol/L)
  • Hypercalcemia (serum calcium > 2.6 mmol/L)
  • Known pregnancy
  • Participation in another clinical trial where the patient receives any other investigational product
  • Unwilling or unable to provide informed consent

Treatment and study plan

Melatonin

Drug

Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.

Vitamin D

Drug

Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.

Placebo (melatonin)

Drug

Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.

Placebo (vitamin D)

Drug

Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.

Primary outcomes

  1. Ki67

    Time frame: From time of initial biopsy to the final surgery, which is on average 4 weeks

    The primary outcome is the difference in proliferation rate of Ki67 in the tumour (expressed as the percentage of tumour cells expressing Ki67). Ki67 will be measured on the original core biopsy (pre-treatment) and on the lumpectomy/mastectomy specimen (post-treatment).

Secondary outcomes

  1. microRNA

    Time frame: At the time of surgery compared to time of biopsy, which is on average 4 weeks

    Change in serum profile of microRNA at the time of surgery (lumpectomy or mastectomy, post-treatment) will be compared to the time of initial biopsy (pre-treatment).

Sponsors and collaborators

Lead sponsor

Juravinski Cancer Center

Other

Registry information

Acronym: MELO-D

Important dates

Study start
2013
Primary completion
2016
Study completion
2017
First posted
Oct 18, 2013
Registry last updated
Jun 16, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.